hydroxyindoleacetic acid and Malignant Carcinoid Syndrome studies

(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.

Malignant Carcinoid Syndrome: A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)

Research Excerpts

Excerpt	Relevance	Reference
"We monitored long-term (median 11 months) concentrations of platelet serotonin and urinary serotonin, 5-hydroxyindoleacetic acid, and seven catecholamine metabolites in 44 patients with carcinoid tumors."	7.69	Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. ( Biesma, B; de Vries, EG; Kema, IP; Muskiet, FA; Slooff, MJ, 1994)
"Sixteen patients with metastatic carcinoid tumor and the malignant carcinoid syndrome were treated with combined cyclophosphamide and methotrexate therapy in a regimen previously described as highly effective."	7.67	Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. ( Moertel, CG; O'Connell, MJ; Reitemeier, RJ; Rubin, J, 1984)
" TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a 12-week double-blind treatment period followed by a 36-week open-label extension (OLE)."	5.27	Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. ( Anthony, LB; Benavent, M; Fleming, D; Fleming, R; Garcia-Carbonero, R; Gross, DJ; Hörsch, D; Jiang, W; Kassler-Taub, K; Kulke, MH; Kunz, PL; Lapuerta, P; Pavel, M; Perros, P; Srirajaskanthan, R; Warner, RRP; Wason, S; Weickert, MO, 2018)
" Carcinoid tumors with liver metastases, especially those of midgut origin, produce serotonin via the precursors tryptophan and 5-hydroxytryptophan (5-HTP) and this overproduction contributes to the clinical symptoms of the carcinoid syndrome."	5.07	Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. ( Ahlström, H; Bergström, M; Eriksson, B; Långström, B; Lilja, A; Oberg, K, 1993)
"One hundred eighteen patients with metastatic carcinoid tumor were randomized to treatment with streptozotocin combined with cyclophosphamide or with 5-fluorouracil (5-FU)."	5.04	Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. ( Hanley, JA; Moertel, CG, 1979)
"The authors conducted a retrospective chart review of patients with carcinoid tumors and elevated serotonin levels (as measured by 24-hour urine 5-hydroxyindoleacetic acid [5-HIAA]) at Dana-Farber/Brigham and Women's Cancer Center who initiated treatment with serotonergic antidepressants after a carcinoid diagnosis from 2003 to 2016."	3.85	Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. ( Brais, LK; Braun, IM; Chan, JA; Dutton, T; Kulke, MH; Meyer, FL; Minden, SL; Shi, DD; Yuppa, DP, 2017)
" The presence of carcinoid heart disease and high urinary output of 5-hydroxyindoleacetic acid preoperatively were statistically significant risk factors for perioperative complications."	3.71	Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. ( Kinney, MA; Maxson, PM; Nagorney, DM; Rubin, J; Schroeder, DR; Warner, MA; Warner, ME, 2001)
"We monitored long-term (median 11 months) concentrations of platelet serotonin and urinary serotonin, 5-hydroxyindoleacetic acid, and seven catecholamine metabolites in 44 patients with carcinoid tumors."	3.69	Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. ( Biesma, B; de Vries, EG; Kema, IP; Muskiet, FA; Slooff, MJ, 1994)
"To characterize a disorder of episodes of flushing and increased levels of 5-hydroxyindoleacetic acid (5-HIAA) in men with secondary hypogonadism who respond to testosterone therapy."	3.69	Pseudocarcinoid syndrome associated with hypogonadism and response to testosterone therapy. ( Drake, AJ; Eisold, JF; Jasser, MZ; Shakir, KM; Yoshihashi, AK, 1996)
"Sixteen patients with metastatic carcinoid tumor and the malignant carcinoid syndrome were treated with combined cyclophosphamide and methotrexate therapy in a regimen previously described as highly effective."	3.67	Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. ( Moertel, CG; O'Connell, MJ; Reitemeier, RJ; Rubin, J, 1984)
"To correlate clinical and laboratory variables in carcinoid heart disease, clinical data, echocardiograms, 24-hour urinary 5-hydroxyindoleacetic acid levels and liver function tests were evaluated in 30 patients with the carcinoid syndrome."	3.67	Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. ( Himelman, RB; Schiller, NB, 1989)
"Seventy-one patients were treated."	2.71	Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. ( Arnold, R; Bax, N; Caplin, M; de Herder, WW; Delle Fave, G; Ducreux, M; Eriksson, B; Glaser, B; Grossman, A; Ish-Shalom, S; Lombard-Bohas, C; O'Toole, D; Reed, N; Rougier, P; Ruszniewski, P; Schmidt, W; Seitz, JF; Tomassetti, P; Van Cutsem, E; Wiedenmann, B; Wymenga, M, 2004)
" Of the 19 patients given alpha-interferon in combination with octreotide, 72% showed significant reduction in urinary 5-HIAA for a median of 10 months."	2.67	Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. ( Janson, ET; Oberg, K, 1993)
"Six of the 8 carcinoid patients had radiographic changes of increased necrosis."	2.67	Somatostatin analogue phase I trials in neuroendocrine neoplasms. ( Anthony, L; Hande, K; Johnson, D; Krozely, M; Oates, J; Shaff, M; Winn, S, 1993)
"Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially."	2.53	Neuroendocrine Tumors. ( Basuroy, R; Ramage, JK; Srirajaskanthan, R, 2016)
"Carcinoid tumors are amine precursor uptake decarboxylase (APUD) omas that arise from enterochromaffin cells throughout the gut."	2.45	Carcinoid tumors of the gastrointestinal tract. ( Anand, S; Ghevariya, N; Ghevariya, V; Malieckal, A; Mazumder, M, 2009)
"Certainly in treatment of the carcinoid tumor surgery has a well-established curative and palliative potential."	2.36	Treatment of the carcinoid tumor and the malignant carcinoid syndrome. ( Moertel, CG, 1983)
"Testicular carcinoid, a rare disease accounting for less than 1% of all testicular neoplasms, rarely manifests symptoms of carcinoid syndrome."	1.32	Primary carcinoid tumor of the bilateral testis associated with carcinoid syndrome. ( Jeong, JO; Kim, GS; Kim, MS; Kim, WB; Koh, EH; Koh, JM; Lee, HI; Lee, KU; Park, JY; Ra, SW; Shong, YK; Son, HY, 2004)
"Pancreatic and midgut carcinoids are metastatic at diagnosis more often than those arising in other locations, leading to a worse overall prognosis."	1.31	Gastrointestinal carcinoids: characterization by site of origin and hormone production. ( Feldman, JM; Hayward, TZ; Kirshbom, PM; Onaitis, MW; Quayle, FJ; Seigler, HF; Tyler, DS, 2000)
"The large diameter of the primary carcinoid tumor and the higher age are the bad prognostic factors in patients with carcinoid tumors."	1.31	The occurrence of malignant carcinoid syndrome in patients with carcinoid tumors. ( Bulas, J; Duris, I; Jurkovicova, I; Kinova, S; Kovacova, E; Makaiova, I; Murin, J; Stenova, E, 2002)
" Dose escalation was required in order to control carcinoid symptoms, and the final dosage was 5,950 micrograms/day."	1.29	Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. ( Deguchi, H; Deguchi, K; Iwasaki, E; Kobayashi, T; Murashima, S; Shirakawa, S; Tsuda, M; Tsukada, T, 1994)
"5-Hydroxyindoleacetic acid and serotonin were elevated."	1.29	[Pronounced flush symptoms in carcinoid syndrome without liver metastases]. ( Hammar, CH; Raschka, C; Roth, J, 1994)
"After one month of treatment, flushing episodes (median (range)) decreased significantly (3 (0."	1.29	Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. ( Bernades, P; Blumberg, J; Chayvialle, JA; Cloarec, D; Ducreux, M; Dupas, JL; Genestin, E; Gouerou, H; Jian, R; Michel, H; Raymond, JM; Rougier, P; Ruszniewski, P, 1996)
"14 patients with metastatic carcinoid tumour were treated with recombinant interferon alfa 6-30 x 10(6) IU weekly for 3-25 (median 6."	1.28	Treatment of metastatic carcinoid tumour with recombinant interferon alfa. ( Gröhn, P; Joensuu, H; Kumpulainen, E, 1992)
"The case of a carcinoid tumor with a hepatic metastasis is presented and its clinical as well as its biochemical and its morphological results are evaluated after treatment with octreotide over a seven months period."	1.28	[Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor]. ( Goñi, F; Goñi, MJ; González, A; Llorente, I; Moncada, E; Monreal, M; Oleaga, A; Yoldi, A, 1991)
"Seventeen patients with malignant carcinoid tumour, ten of whom had the malignant carcinoid syndrome, were treated with recombinant alpha-2b interferon by subcutaneous injection (3 MU per dose) three times per week for a median of 12 weeks (range 4-48)."	1.28	Recombinant alpha-2b interferon in patients with malignant carcinoid tumour. ( Basser, RL; Fox, RM; Green, MD; Lieschke, GJ; Sheridan, WP, 1991)
"Twenty patients with malignant carcinoid tumors were treated for 6 months with recombinant interferon alfa-2b (IFN alpha-2b; Intron-A; Schering Corp."	1.28	Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. ( Alm, G; Lundqvist, G; Magnusson, A; Oberg, K; Theodorsson, E; Wide, L; Wilander, E, 1989)
"We treated nine patients who had carcinoid tumors of the small intestine, six of whom had the carcinoid syndrome, with daily intramuscular doses of leukocyte interferon--3 X 10(6) U per day for one month and 6 X 10(6) U per day for another two months."	1.27	Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. ( Alm, G; Funa, K; Oberg, K, 1983)
"Calcium infusion induced carcinoid symptoms in only two of six patients, which were associated with elevated 5-HT levels (whereas elevated SP levels were seen in only one patient)."	1.27	The pentagastrin test in the diagnosis of the carcinoid syndrome. ( Ahlman, H; Dahlström, A; Grönstad, K; Jaffe, BM; Nilsson, O; Oberg, K, 1985)
"Recurrent and very severe carcinoid symptoms could be observed; a bronchial carcinoid supposingly the primary tumour without characteristic symptoms was removed six years before."	1.27	Hepatic artery embolisation--new approach for treatment of malignant carcinoid syndrome. ( Jermendy, G; Kárpáti, P; Kónya, A, 1986)
"Twelve carcinoid patients and six controls were given alcohol and the kallikrein activity was measured before and at 2, 5, and 10 minutes after alcohol ingestion; kallikrein activity did not change significantly."	1.27	Flushing in the carcinoid syndrome and plasma kallikrein. ( Feldman, JM; Lucas, KJ, 1986)
"Seven patients with progressive ileal or caecal carcinoid tumors and liver metastases were treated with human recombinant alpha-interferon (IFN alfa-2b) at a dosage of 2-4 x 10(6) U daily or every other day subcutaneously."	1.27	[Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon]. ( Doberauer, C; Kloke, O; Kurschel, E; Niederle, N; Schmidt, CG, 1987)
"Eight patients with metastatic carcinoid tumors and the carcinoid syndrome were treated with gelatin foam embolization of the hepatic arterial tree."	1.27	Embolization of the liver in the management of metastatic carcinoid tumors. ( Bengmark, S; Lunderquist, A; Mårtensson, H; Nobin, A; Owman, T; Sandén, G, 1984)
"None of the twenty-nine patients with carcinoid tumours had clinical or laboratory evidence of the ectopic ACTH syndrome."	1.26	Urinary free cortisol excretion in patients with hyperserotoninaemia from the carcinoid syndrome. ( Feldman, JM, 1979)
"These arthropathies have been the subject of only a very limited number of publications."	1.26	[Joint manifestations of carcinoid tumors of the digestive system]. ( Solnica, J, 1976)
"Forty-eight cases of primary insular carcinoid of the ovary were analyzed from a clinicopathologic viewpoint."	1.25	Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. ( Norris, HJ; Robboy, SJ; Scully, RE, 1975)
"Treatment with cyproheptadine caused a documented response in the patient's debilitating diarrhoea and also produced symptomatic improvement in her muscular power."	1.25	Carcinoid myopathy and treatment with cyproheptadine (Periactin). ( Berry, EM; Maunder, C; Wilson, M, 1974)
"Four patients with a malignant carcinoid tumour of the small bowel (three had the carcinoid syndrome) developed gangrene of the small intestine."	1.25	Malignant carcinoid tumour with gangrene of the small intestine. ( Marshall, AK; Murray-Lyon, IM; Rake, MO; Williams, R, 1973)

Research

Studies (201)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Change From Baseline in Abdominal Pain Averaged Across All Time-Points

Timeframe	Studies, this research(%)	All Research%
pre-1990	144 (71.64)	18.7374
1990's	28 (13.93)	18.2507
2000's	14 (6.97)	29.6817
2010's	11 (5.47)	24.3611
2020's	4 (1.99)	2.80

Authors	Studies
Kostiainen, I	1
Karppinen, N	1
Simonen, P	1
Rosengård-Bärlund, M	1
Lindén, R	1
Tarkkanen, M	1
Gordin, D	1
Rapola, J	1
Schalin-Jäntti, C	1
Matikainen, N	1
Buchanan-Hughes, A	1
Pashley, A	1
Feuilly, M	1
Marteau, F	1
Pritchard, DM	1
Singh, S	1
Gut, P	1
Ruchała, M	1
Maurel, J	1
Guimbaud, R	1
Lecomte, T	1
Lièvre, A	1
Hautefeuille, V	1
Robinson, P	1
Francois, L	1
Lombard-Bohas, C	3
Forestier, J	1
Milot, L	1
Subtil, F	1
Walter, T	1
Zandee, WT	1
Brabander, T	1
Blažević, A	1
Minczeles, NS	1
Feelders, RA	2
de Herder, WW	4
Hofland, J	1
Pavel, M	3
Gross, DJ	1
Benavent, M	1
Perros, P	1
Srirajaskanthan, R	2
Warner, RRP	1
Kulke, MH	4
Anthony, LB	2
Kunz, PL	2
Hörsch, D	3
Weickert, MO	1
Lapuerta, P	4
Jiang, W	1
Kassler-Taub, K	1
Wason, S	1
Fleming, R	1
Fleming, D	4
Garcia-Carbonero, R	1
Walsh, JS	1
Newell-Price, JD	1
DeBono, M	1
Adaway, J	1
Keevil, B	2
Eastell, R	1
O'Dorisio, T	1
Phan, A	1
Bergsland, E	2
Law, L	1
Banks, P	3
Freiman, J	1
Frazier, K	1
Jackson, J	1
Yao, JC	1
Kvols, L	1
Zambrowicz, B	3
Sands, A	2
Caplin, M	2
Ramage, J	1
Seufferlein, T	1
Valle, J	1
Wiedenmann, B	2
Basuroy, R	1
Ramage, JK	1
Caplin, ME	1
Öberg, K	11
Welin, S	1
Warner, RR	4
Grande, E	1
Valle, JW	1
Jackson, S	1
Sands, AT	1
Shi, DD	1
Yuppa, DP	1
Dutton, T	1
Brais, LK	1
Minden, SL	1
Braun, IM	1
Chan, JA	1
Meyer, FL	1
Jackson, LN	1
Chen, LA	1
Larson, SD	1
Silva, SR	1
Rychahou, PG	1
Boor, PJ	1
Li, J	1
Defreitas, G	1
Stafford, WL	1
Townsend, CM	1
Evers, BM	1
Ghevariya, V	1
Malieckal, A	1
Ghevariya, N	1
Mazumder, M	1
Anand, S	1
Manickum, T	1
Smith, DF	1
van Dijk, SC	1
Kwekkeboom, DJ	1
Zillikens, MC	1
van Schaik, RH	1
van Driel, M	1
van Leeuwen, JP	1
Hallin, ML	1
Mahmoud, K	1
Viswanath, A	1
Gama, R	1
Piette, C	1
Polus, M	1
Louis, E	1
Møller, JE	1
Connolly, HM	1
Rubin, J	6
Seward, JB	1
Modesto, K	1
Pellikka, PA	1
LANGEMANN, H	2
KAGI, J	1
GOERRE, J	1
PERNOW, B	1
SVANBORG, N	1
HONET, JC	1
CASEY, TV	1
RUNYAN, JW	1
GEFFROY, Y	2
CARTIER, P	1
AUVERT, J	1
MOREAU, J	1
PASQUIS, P	1
DAVIS, RB	1
ROSENBERG, JC	1
JULIAR, B	1
LUETHI, U	1
WENZL, H	1
WASER, PG	1
SPATZ, M	1
WIDELITZ, MM	1
RYBACHOK, TH	1
NASH, DT	1
BRIN, M	1
VAN DER VEER, JS	1
CHOUFOER, JC	1
QUERIDO, A	1
VAN DER HEUL, RO	1
HOLLANDER, CF	1
VAN RIJSSEL, T	1
STRIMLING, MD	1
PICCHIOTTI, R	1
PIETROPAOLO, C	1
ROCCHI, V	1
SJOERDSMA, A	4
MELMON, KL	3
GOBERT, JG	1
SAVEL, J	1
MENGEL, CE	2
KELLY, MG	1
CARBONE, PP	1
ANLYAN, WG	1
HERMAN, Z	1
KINLOCH, JD	1
WEBB, JN	1
ECCLESTON, D	2
ZEITLIN, J	1
CRAWFORD, TB	1
ASHCROFT, GW	1
SMITH, AN	1
LEMONNIER, A	3
CHARPENTIER, C	2
LEMONNIER, F	2
PARAF, A	2
URELES, AL	1
MURRAY, M	1
Son, HY	1
Ra, SW	1
Jeong, JO	1
Koh, EH	1
Lee, HI	1
Koh, JM	1
Kim, WB	1
Park, JY	1
Shong, YK	1
Lee, KU	1
Kim, GS	1
Kim, MS	1
Ruszniewski, P	2
Ish-Shalom, S	1
Wymenga, M	1
O'Toole, D	1
Arnold, R	2
Tomassetti, P	1
Bax, N	1
Eriksson, B	3
Glaser, B	1
Ducreux, M	2
Delle Fave, G	1
Reed, N	1
Seitz, JF	1
Van Cutsem, E	1
Grossman, A	1
Rougier, P	3
Schmidt, W	1
Rorstad, O	1
Shah, GM	1
Shah, RG	1
Veillette, H	1
Kirkland, JB	1
Pasieka, JL	1
van der Lely, AJ	1
Engelman, K	2
Lovenberg, W	1
Rose, D	1
Fornstedt, N	1
Keane, TJ	1
Rider, WD	1
Harwood, AR	1
Thomas, GM	1
Cummings, BJ	1
Feldman, JM	11
Quatrini, M	1
Basilisco, G	1
Conte, D	1
Bozzani, A	1
Bardella, MT	1
Bianchi, PA	1
Harris, AL	1
Smith, IE	1
Funa, K	1
Alm, G	3
Tagari, PC	1
Boullin, DJ	1
Davies, CL	1
Moertel, CG	6
Rosenberg, JM	1
Welch, JP	1
O'Connell, MJ	2
Reitemeier, RJ	1
Taber, M	1
Askenazi, J	1
Ribner, H	1
Kumar, S	1
Lesch, M	1
Mårtensson, H	2
Nobin, A	2
Bengmark, S	1
Lunderquist, A	1
Owman, T	1
Sandén, G	1
Aleshire, SL	1
Bradley, CA	1
Parl, FF	1
Dharmsathaphorn, K	1
Sherwin, RS	1
Cataland, S	1
Jaffe, B	1
Dobbins, J	1
Kema, IP	1
de Vries, EG	1
Slooff, MJ	1
Biesma, B	1
Muskiet, FA	1
Ajani, JA	1
Chesnut, JR	1
Farmer, KL	1
Nold, R	1
Frank, M	1
Kajdan, U	1
Trost, U	1
Klose, KJ	1
Deguchi, H	1
Deguchi, K	1
Tsukada, T	1
Murashima, S	1
Iwasaki, E	1
Tsuda, M	1
Kobayashi, T	1
Shirakawa, S	1
Roth, J	1
Raschka, C	1
Hammar, CH	1
Matuchansky, C	1
Launay, JM	1
Stefănescu, AM	1
Bergström, M	1
Lilja, A	1
Ahlström, H	2
Långström, B	1
Anthony, L	2
Johnson, D	1
Hande, K	1
Shaff, M	1
Winn, S	1
Krozely, M	1
Oates, J	1
Janson, ET	2
Wängberg, B	4
Geterud, K	2
Nilsson, O	4
Jansson, S	2
Dahlström, A	4
Tylén, U	3
Ahlman, H	8
Di Bartolomeo, M	1
Bajetta, E	1
Zilembo, N	1
de Braud, F	1
Di Leo, A	1
Verusio, C	1
D'Aprile, M	1
Scanni, A	1
Barduagni, M	1
Barduagni A [corrected to Barduagni, M]	1
Saslow, SB	1
Camilleri, M	1
Thomforde, GM	1
Van Dyke, CT	1
Pitot, HC	1
Fjälling, M	1
Andersson, P	1
Forssell-Aronsson, E	1
Grétarsdóttir, J	1
Johansson, V	1
Tisell, LE	3
Berg, G	1
Michanek, A	1
Lindstedt, G	1
Bax, ND	1
Mignon, M	1
Morant, R	1
Opolon, P	1
Oberg, KE	2
Shakir, KM	1
Jasser, MZ	1
Yoshihashi, AK	1
Drake, AJ	1
Eisold, JF	1
Chayvialle, JA	2
Blumberg, J	1
Cloarec, D	1
Michel, H	1
Raymond, JM	1
Dupas, JL	1
Gouerou, H	1
Jian, R	1
Genestin, E	1
Bernades, P	1
Parry, RG	1
Glover, S	1
Dudley, CR	1
Warburton, R	1
Ajani, J	1
Schirmer, W	1
Venook, AP	1
Bukowski, R	1
Pommier, R	1
Saltz, L	1
Dandona, P	1
Mahmood, T	1
Mudad, R	1
Onaitis, MW	1
Kirshbom, PM	1
Hayward, TZ	1
Quayle, FJ	1
Seigler, HF	1
Tyler, DS	1
Westberg, G	1
Bergh, CH	1
Beckman-Suurküla, M	1
Caidahl, K	2
Kinney, MA	1
Warner, ME	1
Nagorney, DM	1
Schroeder, DR	1
Maxson, PM	1
Warner, MA	1
Kinova, S	1
Duris, I	1
Bulas, J	1
Murin, J	1
Kovacova, E	1
Stenova, E	1
Jurkovicova, I	1
Makaiova, I	1
Hanley, JA	1
Plonk, JW	2
Admiraal, J	1
Sidbury, JB	1
Lewis, JC	1
Maldonado, JE	1
Mann, KG	1
Farndon, JR	1
Jager, RM	1
Polk, HC	1
Ferrans, VJ	1
Roberts, WC	1
Sivula, A	1
Sipponen, P	1
Solnica, J	1
May, B	1
Jugdutt, BI	1
Watanabe, M	1
Turner, FW	1
Robboy, SJ	1
Norris, HJ	1
Scully, RE	1
Rodríguez-García, JL	1
Arechaga, S	1
Fraile, G	1
Serrano, M	1
Joensuu, H	1
Kumpulainen, E	1
Gröhn, P	1
Tiensuu Janson, EM	1
Andersson, T	1
Goñi, F	1
Oleaga, A	1
Goñi, MJ	1
Monreal, M	1
Yoldi, A	1
González, A	1
Llorente, I	1
Moncada, E	1
Stenqvist, O	2
Scherstén, T	1
Basser, RL	1
Lieschke, GJ	1
Sheridan, WP	1
Fox, RM	1
Green, MD	1
Grönstad, K	1
Jaffe, BM	1
Odurny, A	1
Birch, SJ	1
Sundler, F	1
Falkmer, S	1
Stockdale, AD	1
Leader, M	1
Phillips, RH	1
Henry, K	1
Arora, RR	1
Jermendy, G	1
Kónya, A	1
Kárpáti, P	1
Richter, G	1
Stöckmann, F	1
Conlon, JM	1
Creutzfeldt, W	1
Norheim, I	5
Theodorsson-Norheim, E	3
Brodin, E	1
Kvols, LK	1
Schutt, AJ	1
Hahn, RG	1
Lucas, KJ	1
Varas, MJ	1
Navarro, MA	1
Rosell, P	1
García, F	1
Silva, CE	1
Ortiz, J	1
Lima, AB	1
Matsumoto, AY	1
Marotta, RH	1
Monaco, CA	1
Barretto, AC	1
Wiles, P	1
Hampton, K	1
Dean, H	1
Feely, M	1
Lindgren, PG	1
Lundqvist, G	3
Magnusson, A	2
Wide, L	3
Wilander, E	2
Sjöblom, SM	1
Höckerstedt, K	1
Järvinen, H	1
Lundin, L	1
Landelius, J	1
Doberauer, C	1
Niederle, N	1
Kloke, O	1
Kurschel, E	1
Schmidt, CG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome[NCT02063659]	Phase 3	76 participants (Actual)	Interventional	2014-03-11	Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-A[NCT00853047]	Phase 2	23 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome[NCT01104415]	Phase 2	15 participants (Actual)	Interventional	2010-06-15	Completed
UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036]	Phase 2	50 participants (Anticipated)	Interventional	2021-10-07	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Participants recorded abdominal pain in a daily diary. Participants evaluated the level of any abdominal pain using an 11-point numeric rating scale, where: 0=no pain to 10=worst pain ever experienced. The average daily abdominal pain was averaged over the 12-week period. A negative change from Baseline indicates improvement. (NCT02063659)
Timeframe: Baseline and 12 Weeks

Change From Baseline in Stool Form/Consistency Averaged Across All Time-Points

Intervention	score on a scale (Mean)
Placebo	-0.063
250 mg Telotristat Etiprate	-0.234
500 mg Telotristat Etiprate	0.025

Participants assessed stool form/consistency of a BM using the Bristol Stool Form Scale where: 1=hard lumps to 7=watery liquid. The daily scores were averaged over the 12-week period. A negative change indicates improvement. (NCT02063659)
Timeframe: Baseline and 12 Weeks

Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks

Intervention	score on a scale (Mean)
Placebo	0.006
250 mg Telotristat Etiprate	-0.196
500 mg Telotristat Etiprate	-0.597

Participants recorded the number of bowel movements per day in a daily diary. The total number of BMs per day were averaged over the 12-week period. A negative change from Baseline indicates improvement. (NCT02063659)
Timeframe: Baseline and 12 weeks

Change From Baseline in the Number of Daily BMs Averaged Over the 12-Week Double-Blind Period, Among Participants Who Were Not Receiving SSA Therapy at Baseline

Intervention	counts/day (Mean)
Placebo	0.050
250 mg Telotristat Etiprate	-0.452
500 mg Telotristat Etiprate	-0.595

Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points

Intervention	counts/day (Mean)
250 mg Telotristat Etiprate	-0.906
500 mg Telotristat Etiprate	-0.98

Participants recorded the number daily flushing episodes per day in a daily diary. The total number of flushing episodes per day were averaged over the 12-week period. A negative change from Baseline indicates improvement. (NCT02063659)
Timeframe: Baseline and 12 Weeks

Change in the Frequency of Rescue Short-acting, Somatostatin Analog (SSA) Used to Treat Carcinoid Syndrome Symptoms Averaged Across All Time-Points

Intervention	counts/day (Mean)
Placebo	-0.333
250 mg Telotristat Etiprate	-0.061
500 mg Telotristat Etiprate	0.114

The frequency (the number of times) the participant used rescue with SSA to control symptoms was recorded in a daily diary. The daily number of rescue treatments with SSA was averaged over the 12- week period. A negative change from Baseline (less use of SSA) indicates improvement. (NCT02063659)
Timeframe: Baseline and 12 weeks

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period

Intervention	counts/day (Mean)
Placebo	-0.013
250 mg Telotristat Etiprate	-0.065
500 mg Telotristat Etiprate	0.006

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1. (NCT02063659)
Timeframe: First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.1 Weeks)

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Extension Period

Intervention	Participants (Count of Participants)
Placebo	21
250 mg Telotristat Etiprate	25
500 mg Telotristat Etiprate	22

Primary: Percent Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels

Intervention	Participants (Count of Participants)
Telotristat Etiprate Open-Label Extension	61

u5-HIAA is a standard test used in clinical practice to assess neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. A negative change from Baseline indicates improvement. (NCT02063659)
Timeframe: Baseline and 12 Weeks

Change From Baseline in Chromogranin A

Intervention	percentage change of mg/24 hours (Mean)
Placebo	97.721
250 mg Telotristat Etiprate	-33.164
500 mg Telotristat Etiprate	-76.466

Blood samples were collected for assessment of Chromogranin A level. A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Frequency of Rescue for Short-acting Octreotide Use/Day

Intervention	ng/mL (Mean)
Placebo Core Phase	-3251.2
Telotristat Etiprate 150 mg Core Phase	-190.5
Telotristat Etiprate 250 mg Core Phase	-12.3
Telotristat Etiprate 350 mg Core Phase	52.5
Telotristat Etiprate 500 mg Core Phase	26011.4

Participants recorded details (location and frequency of injection) of subcutaneous injections of rescue, short-acting octreotide, if taken, in the daily diary. A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day

Intervention	injections per day (Mean)
Placebo Core Phase	-0.38
Telotristat Etiprate 150 mg Core Phase	-0.03
Telotristat Etiprate 250 mg Core Phase	0.03
Telotristat Etiprate 350 mg Core Phase	0.00
Telotristat Etiprate 500 mg Core Phase	-0.29

Participants recorded the number of BMs per day in a daily diary. The total number of BMs per day were averaged over the 4-week period. A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Number of Cutaneous Flushing Episodes

Intervention	bowel movements/day (Mean)
Placebo Core Phase	0.82
Telotristat Etiprate 150 mg Core Phase	-1.37
Telotristat Etiprate 250 mg Core Phase	-2.17
Telotristat Etiprate 350 mg Core Phase	-0.20
Telotristat Etiprate 500 mg Core Phase	-0.71

Participants recorded the number of daily flushing episodes per day in a daily diary. The total number of flushing episodes per day were averaged over the 4-week period. A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Percentage of Days Per Week Experiencing a Sensation of Urgency to Defecate

Intervention	cutaneous flushing episodes (Mean)
Placebo Core Phase	-0.43
Telotristat Etiprate 150 mg Core Phase	-0.60
Telotristat Etiprate 250 mg Core Phase	-0.30
Telotristat Etiprate 350 mg Core Phase	-0.10
Telotristat Etiprate 500 mg Core Phase	-0.03

Participants recorded the sensation of urgency to defecate (Yes or No) in a daily diary. A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Severity of Abdominal Pain or Discomfort

Intervention	percentage of days (Mean)
Placebo Core Phase	-2.72
Telotristat Etiprate 150 mg Core Phase	-34.43
Telotristat Etiprate 250 mg Core Phase	-32.13
Telotristat Etiprate 350 mg Core Phase	0.00
Telotristat Etiprate 500 mg Core Phase	-8.49

Participants recorded the severity of abdominal pain or discomfort in a daily diary assessed using a 4-point scale (0-none, 1-mild, 2-moderate, 3-severe). A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA)

Intervention	units on a scale (Mean)
Placebo Core Phase	0.04
Telotristat Etiprate 150 mg Core Phase	0.03
Telotristat Etiprate 250 mg Core Phase	-0.53
Telotristat Etiprate 350 mg Core Phase	0.03
Telotristat Etiprate 500 mg Core Phase	0.16

u5-HIAA is a standard test used in clinical practice to assess the neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Change From Baseline in Weekly Mean Stool Form

Intervention	mg/24 hours (Mean)
Placebo Core Phase	-20.73
Telotristat Etiprate 150 mg Core Phase	-27.55
Telotristat Etiprate 250 mg Core Phase	-0.67
Telotristat Etiprate 350 mg Core Phase	13.60
Telotristat Etiprate 500 mg Core Phase	-35.49

Participants recorded stool form in a daily diary using a 6-point scale (0-none,1-hard, 2-firm, 3-soft, 4-loose, 5-watery). A negative change from Baseline indicates improvement. (NCT00853047)
Timeframe: Baseline to Week 4

Number of Participants Experiencing Complete Response at Week 4

Intervention	units on a scale (Mean)
Placebo Core Phase	-0.07
Telotristat Etiprate 150 mg Core Phase	-0.50
Telotristat Etiprate 250 mg Core Phase	0.00
Telotristat Etiprate 350 mg Core Phase	0.00
Telotristat Etiprate 500 mg Core Phase	-0.17

"Complete Response to treatment was defined as one of the following: 1. Less than 4 bowel movements per day; or 2. A decrease in daily bowel movements that is ≥ 50% from baseline; or 3. A positive response to the global assessment question (In the past 7 days, have you had adequate relief of your carcinoid syndrome bowel complaints such as diarrhea, urgent need to have a bowel movement, abdominal pain or discomfort?) for each of the last 2 weeks of the Treatment Period." (NCT00853047)
Timeframe: Baseline to Week 4

Number of Participants Reporting Improvement in the Subjective Global Assessment of Symptoms Associated With Carcinoid Syndrome

Intervention	Participants (Count of Participants)
Placebo Core Phase	0
Telotristat Etiprate 150 mg Core Phase	1
Telotristat Etiprate 250 mg Core Phase	2
Telotristat Etiprate 350 mg Core Phase	1
Telotristat Etiprate 500 mg Core Phase	2

"Participants were asked to answer the following question: In the past 7 days, have you had adequate relief of your carcinoid syndrome bowel complaints such as diarrhea, urgent need to have a bowel movement, abdominal pain, or discomfort?. The number of participants who answered Yes are reported." (NCT00853047)
Timeframe: Week 4

Number of Participants With Any TEAE in the Open-Label Extension Phase

Intervention	Participants (Count of Participants)
Placebo Core Phase	0
Telotristat Etiprate 150 mg Core Phase	1
Telotristat Etiprate 250 mg Core Phase	2
Telotristat Etiprate 350 mg Core Phase	1
Telotristat Etiprate 500 mg Core Phase	3

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after receiving treatment. (NCT00853047)
Timeframe: Up to 180 weeks in the open-label extension phase

Time to First Rescue, Short-acting Octreotide

Intervention	Participants (Count of Participants)
Telotristat Etiprate Open-Label Extension Phase	18

Time to the first subcutaneous injections of rescue, short-acting octreotide was determined from the participant's daily diary. (NCT00853047)
Timeframe: Baseline to Week 4

Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase

Intervention	days (Median)
Placebo Core Phase	1.00
Telotristat Etiprate 500 mg Core Phase	1.00

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1. (NCT00853047)
Timeframe: Up to 4 Weeks Core Phase

Change From Baseline in Daily Number of Cutaneous Flushing Episodes

Intervention	Participants (Count of Participants)
	Any TEAE	Related TEAEs
Placebo Core Phase	4	3
Telotristat Etiprate 150 mg Core Phase	3	3
Telotristat Etiprate 250 mg Core Phase	3	0
Telotristat Etiprate 350 mg Core Phase	2	2
Telotristat Etiprate 500 mg Core Phase	9	6

Participants recorded the number of daily cutaneous flushing episodes experienced in the daily diary. The change from baseline value was calculated as the difference between the mean numbers of cutaneous flushing episodes of the post-baseline interval (Weeks 9 to 12) and baseline. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. (NCT01104415)
Timeframe: Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24

Change From Baseline in Daily Severity of Abdominal Pain or Discomfort Using 100 mm Visual Analog Scale (VAS)

Intervention	Daily number of flushing episodes (Mean)
Telotristat Etiprate- Core Phase	-0.88
Telotristat Etiprate- Extension Period	-1.55

The severity of abdominal pain was measured using a 100 mm VAS. Participants rated their perception of the sensation/severity of abdominal pain or experienced by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No vomiting and 100 = vomiting. The change from the baseline value was calculated as the difference between the mean score of the post-baseline interval (Weeks 9 to 12) and baseline. 0 indicate the best score, 100 indicates the worst score. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. (NCT01104415)
Timeframe: Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24

Change From Baseline in Number of Bowel Movements (BMs)

Intervention	score on a scale (Mean)
Telotristat Etiprate- Core Phase	-8.66
Telotristat Etiprate- Extension Period	-24.11

Participants recorded the number of bowel movements in a daily diary. The change from baseline value was calculated as the difference between mean numbers of BMs of the post-baseline interval (Weeks 9 to 12) and baseline. A negative change from baseline indicates improvement. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. (NCT01104415)
Timeframe: Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24

Change From Baseline in Percentage of Days With Sensation of Urgency to Defecate

Intervention	number of bowel movements/day (Mean)
Telotristat Etiprate- Core Phase	-2.60
Telotristat Etiprate- Extension Period	-2.85

"Participants assessed the urgency to defecate using a daily diary response to the following question, Have you felt or experienced a sense of urgency to pass stool today?. The change from the baseline value was calculated as the difference between the mean score (percentage of days) of the post-baseline interval (Weeks 9 to 12) and baseline. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug." (NCT01104415)
Timeframe: Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24

Change From Baseline in Sensation/Severity of Nausea Using 100 mm Visual Analog Scale (VAS)

Intervention	percentage of days (Mean)
Telotristat Etiprate- Core Phase	-11.32
Telotristat Etiprate- Extension Period	-22.79

Sensation/severity of nausea was measured using a 100 mm VAS. Participants rated their perception of the sensation/severity of nausea experienced by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No vomiting and 100 = vomiting. The change from the baseline value was calculated as the difference between the mean score of the post-baseline interval (Weeks 9 to 12) and baseline. 0 indicates the best score, 100 indicates the worst score. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. (NCT01104415)
Timeframe: Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24

Change From Baseline in Stool Form/Consistency

Intervention	score on a scale (Mean)
Telotristat Etiprate- Core Phase	-2.43
Telotristat Etiprate- Extension Period	-5.71

Participants assessed stool form/consistency in a daily diary using a 6-point scale (0-none, 1-hard, 2-firm, 3-soft, 4-loose, 5-watery). The change from the baseline value was calculated as the difference between a mean score of the post-baseline interval (Weeks 9 to 12) and baseline. 0 indicates the best score and 5 indicates the worst score. A negative change from baseline indicates improvement. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. (NCT01104415)
Timeframe: Core Phase: Baseline to Weeks 9-12; Extension Period: Baseline to Week 24

Change From Baseline in Urinary 5-Hydroxyindoleacetic Acid (HIAA) Levels

Intervention	score on a scale (Mean)
Telotristat Etiprate- Core Phase	-0.79
Telotristat Etiprate- Extension Period	-1.31

Urinary 5-HIAA (u5-HIAA) is a standard test used in clinical practice to assess the neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. The change from baseline value for the Extension Period was calculated as the difference between mean change in 5-HIAA of the post-baseline interval (Weeks 20 to 21) and baseline. A negative change from baseline indicates improvement. Baseline for the Extension Period was defined as non-missing assessment in Run-in period prior to the first dose of study drug. (NCT01104415)
Timeframe: Core Phase: Baseline to Week 12; Extension Period: Baseline to Weeks 20-21

Number of Participants Achieving Clinically Meaningful Symptom Reduction in the Core Phase

Intervention	mg/24 hours (Mean)
Telotristat Etiprate- Core Phase	-97.26
Telotristat Etiprate- Extension Period	-65.02

Clinically meaningful symptom reduction was defined as either: a) an average of < 4 bowel movements per day over 15 consecutive days, b) a 50% reduction from baseline in the number of bowel movements, c) a positive response to the question regarding adequate relief, or d) a 50% reduction from baseline in the number of daily flushing episodes. (NCT01104415)
Timeframe: Baseline to Week 12

Number of Participants With an Improvement in Global Assessment of Symptoms Associated With Carcinoid Syndrome

Intervention	Participants (Count of Participants)
Telotristat Etiprate- Core Phase	14

"Participants assessed their symptoms using a weekly subjective response to the following question, In the past 7 days, have you had adequate relief of your carcinoid syndrome bowel complaints such as diarrhea, urgent need to have a bowel movement, abdominal pain, or discomfort?. The values for improvement in global assessment of symptoms associated with carcinoid syndrome in the Core Phase were averaged from Weeks 9 to 12." (NCT01104415)
Timeframe: Core Phase: Weeks 9-12; Extension Period: Week 24

Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase

Intervention	Participants (Count of Participants)
Telotristat Etiprate- Core Phase	10
Telotristat Etiprate- Extension Period	4

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. Treatment-emergent AEs were defined as any AEs reported after the first dose of treatment on Day 1. (NCT01104415)
Timeframe: Baseline up to Week 12 in the Core Phase

Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Extension Period

Intervention	Participants (Count of Participants)
	Any TEAE	Drug-Related TEAE
Telotristat Etiprate- Core Phase	15	5

Reviews

16 reviews available for hydroxyindoleacetic acid and Malignant Carcinoid Syndrome

Trials

16 trials available for hydroxyindoleacetic acid and Malignant Carcinoid Syndrome

Other Studies

169 other studies available for hydroxyindoleacetic acid and Malignant Carcinoid Syndrome

Article	Year
Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review. Neuroendocrinology, 2021, Volume: 111, Issue:1-2 Topics: Carcinoid Heart Disease; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrom	2021
Neuroendocrine Tumors. Gastroenterology clinics of North America, 2016, Volume: 45, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chromogranin A; Digestive System Surgical Pr	2016
Carcinoid tumors of the gastrointestinal tract. Southern medical journal, 2009, Volume: 102, Issue:10 Topics: Antineoplastic Agents; Carcinoid Tumor; Chemoembolization, Therapeutic; Chromogranins; Diagnostic Im	2009
[Pathological implications in the neuroendocrine gastrointestinal system]. Revue medicale de Liege, 2002, Volume: 57, Issue:8 Topics: Carcinoid Tumor; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic	2002
DIAGNOSIS AND MANAGEMENT OF MALIGNANT CARCINOID SYNDROME: A REVIEW. Clinical medicine (Northfield, Ill.), 1964, Volume: 71 Topics: Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Neoplasm Metastasis; Neoplasms; Sele	1964
Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. Journal of surgical oncology, 2005, Mar-01, Volume: 89, Issue:3 Topics: Biomarkers, Tumor; Carcinoid Heart Disease; Carcinoid Tumor; Chromogranin A; Chromogranins; Gastroin	2005
Carcinoid syndrome: diagnosis and medical management. Arquivos brasileiros de endocrinologia e metabologia, 2005, Volume: 49, Issue:5 Topics: Biomarkers, Tumor; Chromogranin A; Chromogranins; Gastrointestinal Neoplasms; Humans; Hydroxyindolea	2005
Treatment of the carcinoid tumor and the malignant carcinoid syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Ap	1983
The carcinoid syndrome: neuroendocrine and chemical considerations. Clinics in laboratory medicine, 1984, Volume: 4, Issue:4 Topics: Endocrine Glands; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Kinins; Malignant Ca	1984
Additional tests of interest to the dermatologist. Dermatologic clinics, 1994, Volume: 12, Issue:1 Topics: alpha 1-Antitrypsin Deficiency; Angioedema; Complement C1 Inactivator Proteins; Erythema; Glucagon;	1994
[Carcinoid: diagnosis and therapy]. Deutsche medizinische Wochenschrift (1946), 1975, Oct-17, Volume: 100, Issue:42 Topics: Aprotinin; Bradykinin; Carcinoid Heart Disease; Carcinoid Tumor; Cyproheptadine; Diagnosis, Differen	1975
[Current views on carcinoid and the carcinoid syndrome]. Klinicheskaia meditsina, 1971, Volume: 49, Issue:1 Topics: 1-Propanol; 5-Hydroxytryptophan; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carcinoi	1971
Functioning primary carcinoid tumor of the ovary. A light- and electron-microscopic study with review of the literature. American journal of clinical pathology, 1974, Volume: 62, Issue:5 Topics: Aged; Ankle; Appendix; Carcinoid Tumor; Diarrhea; Edema; Female; Hepatomegaly; Humans; Hydroxyindole	1974
[Endocrine disorders in neoplasms of the respiratory system]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1974, Aug-01, Volume: 27, Issue:15 Topics: Adrenal Cortex Hormones; Bronchial Neoplasms; Cushing Syndrome; Endocrine System Diseases; Gynecomas	1974
The role of 5-hydroxyindoles in the carcinoid syndrome. Advances in pharmacology, 1968, Volume: 6, Issue:Pt B Topics: Humans; Hydroxyindoleacetic Acid; Indoles; Malignant Carcinoid Syndrome; Serotonin	1968
Progress report: the carcinoid syndrome. Gut, 1970, Volume: 11, Issue:2 Topics: 5-Hydroxytryptophan; Antineoplastic Agents; Bradykinin; Diarrhea; Heart Valve Diseases; Humans; Hydr	1970

Article	Year
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-related cancer, 2018, Volume: 25, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Female; Humans; Hydroxyindoleacetic A	2018
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocrine-related cancer, 2014, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Diarrhea; Female; Gastrointestinal	2014
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:4 Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Female; Flushing; Gastrointestinal Transit; Humans;	2015
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Agents, Hormonal; Defecation; Diarrhea; Double-Blind Method; Female; gamma-Glut	2017
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology, 2004, Volume: 80, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Chromogranins; Delayed-Action Preparations; Dose-Response Relationsh	2004
Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. The New England journal of medicine, 1967, Nov-23, Volume: 277, Issue:21 Topics: Adult; Aged; Amino Acids; Female; Humans; Hydroxyindoleacetic Acid; Ileum; Indoles; Male; Malignant	1967
Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:2 Topics: 5-Hydroxytryptophan; Adenoma, Islet Cell; Carbon Radioisotopes; Carcinoid Tumor; Female; Gastrointes	1993
Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:2 Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoid Tumor; Dose-Response Relationship	1993
Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Dos	1993
Treatment of carcinoid syndrome with recombinant interferon alpha-2a. Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:2 Topics: Adult; Aged; Carcinoid Tumor; Drug Administration Schedule; Female; Humans; Hydroxyindoleacetic Acid	1993
The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion, 1996, Volume: 57 Suppl 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers,	1996
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2 Topics: Carcinoid Tumor; Delayed-Action Preparations; Diarrhea; Dose-Response Relationship, Drug; Double-Bli	1999
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer clinical trials, 1979,Winter, Volume: 2, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Child; Clinical Trials as Topic; Cy	1979
The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. The Journal of clinical endocrinology and metabolism, 1989, Volume: 68, Issue:4 Topics: Aged; Double-Blind Method; Female; Flushing; Humans; Hydroxyindoleacetic Acid; Insulin; Intestinal N	1989
Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Hydroxyindoleace	1989
Failure of epinephrine to provoke flushing in patients with systemic mastocytosis. Annals of internal medicine, 1971, Volume: 74, Issue:5 Topics: Adult; Biopsy; Blood Pressure; Blushing; Diagnosis, Differential; Epinephrine; Female; Humans; Hydro	1971

Article	Year
Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours. Endocrine, 2022, Volume: 77, Issue:1 Topics: Biomarkers; Carcinoid Heart Disease; Carcinoid Tumor; Cross-Sectional Studies; Humans; Hydroxyindole	2022
Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. Neuro endocrinology letters, 2019, Volume: 40, Issue:7-8 Topics: Aged; Antineoplastic Agents, Hormonal; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasm	2019
Value of a patient-reported-outcome measure of carcinoid syndrome symptoms. European journal of endocrinology, 2021, Volume: 184, Issue:5 Topics: Aged; Cohort Studies; Female; Food; France; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcin	2021
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. The Journal of clinical endocrinology and metabolism, 2021, 08-18, Volume: 106, Issue:9 Topics: Aged; Aged, 80 and over; Cohort Studies; Diarrhea; Drug Resistance, Neoplasm; Female; Humans; Hydrox	2021
Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:7 Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Case-Contro	2013
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. Cancer, 2017, Jul-15, Volume: 123, Issue:14 Topics: Anxiety; Carcinoid Tumor; Depression; Diarrhea; Female; Flushing; Humans; Hydroxyindoleacetic Acid;	2017
Development and characterization of a novel in vivo model of carcinoid syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-15, Volume: 15, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo	2009
Simultaneous analysis of neuroendocrine tumor markers by HPLC-electrochemical detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Dec-15, Volume: 877, Issue:32 Topics: Adrenal Gland Neoplasms; Adult; Biomarkers, Tumor; Child; Child, Preschool; Chromatography, High Pre	2009
Case report--carcinoid syndrome: two case reports from reserve unit. Journal of the Royal Naval Medical Service, 2011, Volume: 97, Issue:2 Topics: Adult; Antineoplastic Agents, Hormonal; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid	2011
5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. Bone, 2012, Volume: 50, Issue:6 Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Cell Differentiation; Cell Line; Female; Hum	2012
'Sweet Dreams', 'Happy Days' and elevated 24-h urine 5-hydroxyindoleacetic acid excretion. Annals of clinical biochemistry, 2013, Volume: 50, Issue:Pt 1 Topics: 5-Hydroxytryptophan; Aged; Chromatography, High Pressure Liquid; Chromogranin A; False Positive Reac	2013
Factors associated with progression of carcinoid heart disease. The New England journal of medicine, 2003, Mar-13, Volume: 348, Issue:11 Topics: Aged; Carcinoid Heart Disease; Disease Progression; Echocardiography, Doppler; Female; Heart Valve D	2003
[Hydroxytryptamine and hydroxyindolacetic acid determination in a case of carcinoid syndrome, with a study on hydroxytryptamine]. Klinische Wochenschrift, 1956, Mar-01, Volume: 34, Issue:9-10 Topics: Biochemical Phenomena; Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndro	1956
[Suppression of hydroxyindole-acetic acid excretion in urine after reserpine administration in humans; with special consideration to carcinoid syndrome]. Schweizerische medizinische Wochenschrift, 1957, May-25, Volume: 87, Issue:21 Topics: Acetates; Carcinoid Tumor; Gastrointestinal Tract; Hydroxyindoleacetic Acid; Indoleacetic Acids; Mal	1957
[Value of 5-hydroxyindoleacetic acid analysis in the early diagnosis of carcinoids: case report]. Svenska lakartidningen, 1958, Aug-15, Volume: 55, Issue:33 Topics: Carcinoid Tumor; Early Diagnosis; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Ca	1958
False-positive urinary test for 5-hydroxyindoleacetic acid due to methocarbamol and mephenesin carbamate. The New England journal of medicine, 1959, Jul-23, Volume: 261, Issue:4 Topics: Carbamates; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Carcinoid Syndrome; Mephenesin;	1959
[A recent observation of carcinoidosis. Concomitant urinary elimination of 5-hydroxyindolacetic acid and other indole derivatives. Clinical and biochemical study]. La Presse medicale, 1961, Sep-27, Volume: 69 Topics: Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Carcinoid Syndrome	1961
Carcinoid syndrome associated with hyperserotoninemia and normal 5-hydroxyindoleacetic acid excretion. The American journal of medicine, 1961, Volume: 30 Topics: Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Carcinoid Syndrome; Medical Records;	1961
CARCINOID SYNDROME: REPORT OF CASE. Bulletin - Sinai Hospital of Detroit, 1963, Volume: 11 Topics: Carcinoid Tumor; Chlorpromazine; Cyproheptadine; Geriatrics; Humans; Hydroxyindoleacetic Acid; Malig	1963
[THE STORAGE OF C14-LABELLED TRYPTOPHAN IN A METASTASIZING SMALL INTESTINE CARCINOID]. Klinische Wochenschrift, 1964, Jan-01, Volume: 42 Topics: Autoradiography; Carbon Isotopes; Hydroxyindoleacetic Acid; Intestine, Small; Malignant Carcinoid Sy	1964
PATHOGENETIC STUDIES OF EXPERIMENTALLY INDUCED HEART LESIONS AND THEIR RELATION TO THE CARCINOID SYNDROME. Laboratory investigation; a journal of technical methods and pathology, 1964, Volume: 13 Topics: Chemical and Drug Induced Liver Injury; Deficiency Diseases; Diet; Guinea Pigs; Heart Diseases; Hepa	1964
THORSON BIOERCK SYNDROME WITH HIGH LEVELS OF 5 HYDROXYINDOLEACTEIC ACID WITHOUT CARCINOID TUMOR. Journal of the Germantown Hospital, 1964, Volume: 5 Topics: Autopsy; Bronchial Diseases; Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids;	1964
MALABSORPTION IN MALIGNANT CARCINOID WITH NORMAL 5 HIAA. New York state journal of medicine, 1964, May-01, Volume: 64 Topics: Blood Chemical Analysis; Celiac Disease; Fluorouracil; Hydroxyindoleacetic Acid; Indoleacetic Acids;	1964
METASTASISING ISLET-CELL TUMOUR OF THE PANCREAS ASSOCIATED WITH HYPOGLYCAEMIA AND CARCINOID SYNDROME. Lancet (London, England), 1964, Jun-27, Volume: 2, Issue:7348 Topics: Adenoma, Islet Cell; Cortisone; Ergot Alkaloids; Humans; Hydroxyindoleacetic Acid; Hypoglycemia; Ind	1964
BRONCHIAL ADENOMA (CARCINOID TYPE) WITH HYPERSEROTONINEMIA AND UNUSUAL ROENTGENOGRAPHIC MANIFESTATIONS. REPORT OF A CASE. Diseases of the chest, 1964, Volume: 45 Topics: Adenoma; Bronchial Neoplasms; Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids;	1964
[ON A CASE OF METASTATIC FUNCTIONING ILEAL CARCINOID. OBSERVATIONS AND CONSIDERATIONS 3 YEARS AFTER SURGICAL INTERVENTION]. Gazzetta internazionale di medicina e chirurgia, 1963, Dec-31, Volume: 67 Topics: Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Hypertension; Ileum; Indoleacetic Acids; Intestin	1963
THE CARCINOID SPECTRUM. Gastroenterology, 1964, Volume: 47 Topics: 5-Hydroxytryptophan; Angiotensins; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; Chlo	1964
SEVERE FLUSHING REACTIONS RESPONSIVE TO STEROIDS IN PATIENTS WITH BRONCHIAL CARCINOID. Lancet (London, England), 1964, Oct-10, Volume: 2, Issue:7363 Topics: Bronchial Neoplasms; Chlorpromazine; Chromatography; Diagnosis, Differential; Humans; Hydroxyindolea	1964
[SEMI-QUANTITATIVE DETERMINATION OF 5-HYDROXYINDOLIC DERIVATIVES IN THE BLOOD, URINE AND TISSUES]. Pathologie et biologie, 1964, Volume: 12 Topics: 5-Hydroxytryptophan; Biomedical Research; Blood; Bronchial Neoplasms; Chromatography; Histology; Hyd	1964
[THE CARCINOID SYNDROME (APROPOS OF 7 CASES)]. Pathologie et biologie, 1964, Volume: 12 Topics: Geriatrics; Growth Hormone; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Carcinoi	1964
CLINICAL AND BIOCHEMICAL EFFECTS OF CYCLOPHOSPHAMIDE IN PATIENTS WITH MALIGNANT CARCINOID. The American journal of medicine, 1965, Volume: 38 Topics: Blood; Carcinoid Tumor; Cyclophosphamide; Drug Therapy; Geriatrics; Humans; Hydroxyindoleacetic Acid	1965
[EFFECT OF NIAMIDE ON THE BLOOD LEVEL 5-HYDROXYTRYPTAMINE AND ON THE URINARY EXCRETION OF 5-HYDROXYINDOLACETIC ACID IN PATIENTS WITH MALIGNANT CARCINOID SYNDROME]. Polskie Archiwum Medycyny Wewnetrznej, 1964, Volume: 34 Topics: Blood; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Malignant Carcinoid Syndrome; Nialamide	1964
CARCINOID SYNDROME ASSOCIATED WITH OAT-CELL CARCINOMA OF BRONCHUS. British medical journal, 1965, Jun-12, Volume: 1, Issue:5449 Topics: Aprotinin; Aspirin; Avena; Bronchi; Bronchial Neoplasms; Carcinoma; Chlorpromazine; Drug Therapy; En	1965
SOME OBSERVATIONS ON THE METABOLISM OF INDOLES IN TWO PATIENTS WITH THE CARCINOID SYNDROME. Gastroenterology, 1965, Volume: 48 Topics: 5-Hydroxytryptophan; Biochemical Phenomena; Biochemistry; Blood; Cerebrospinal Fluid; Chromatography	1965
[CURRENT DATA ON BIOCHEMISTRY OF THE CARCINOID SYNDROME]. Revue medico-chirurgicale des maladies du foie, 1965, Volume: 40 Topics: 5-Hydroxytryptophan; Amino Acids; Biochemistry; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoi	1965
[METABOLIC CHANGES OBSERVED IN THE COURSE OF HEPATIC CARCINOIDOSIS OF PROBABLE BRONCHIAL ORIGIN]. Revue medico-chirurgicale des maladies du foie, 1965, Volume: 40 Topics: Amino Acids; Humans; Hydroxyindoleacetic Acid; Intestinal Absorption; Liver; Malignant Carcinoid Syn	1965
[CLINICAL STUDY OF HEPATIC CARCINOIDOSIS OF PROBABLE BRONCHIAL ORIGIN FOLLOWED FOR 2 YEARS]. Revue medico-chirurgicale des maladies du foie, 1965, Volume: 40 Topics: Bronchial Diseases; Humans; Hydroxyindoleacetic Acid; Liver Diseases; Malignant Carcinoid Syndrome;	1965
[ATTEMPTS AT MEDICAL TREATMENT OF THE CARCINOID SYNDROME. GENERAL REVIEW AND PERSONAL TRAILS]. Revue medico-chirurgicale des maladies du foie, 1965, Volume: 40 Topics: 5-Hydroxytryptophan; Amino Acids; Biochemical Phenomena; Drug Therapy; Humans; Hydroxyindoleacetic A	1965
Primary carcinoid tumor of the bilateral testis associated with carcinoid syndrome. International journal of urology : official journal of the Japanese Urological Association, 2004, Volume: 11, Issue:11 Topics: Adult; Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Orchie	2004
Biochemical assessment of niacin deficiency among carcinoid cancer patients. The American journal of gastroenterology, 2005, Volume: 100, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoid Tumor; Case-Control Studies; Cohort Studies; Female; Gastr	2005
Carcinoid syndrome. The American journal of nursing, 1980, Volume: 80, Issue:1 Topics: Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Palliative Care	1980
High-performance liquid chromatographic determination of 5-hydroxyindole-3-acetic acid in urine using Sephadex G-10 for isolation. Journal of chromatography, 1980, Mar-14, Volume: 181, Issue:3-4 Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Female; Homov	1980
Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor. International journal of radiation oncology, biology, physics, 1981, Volume: 7, Issue:11 Topics: Abdomen; Adult; Aged; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacet	1981
Metabolic acidosis in patients with the carcinoid syndrome: treatment with parachlorophenylalanine. Journal of surgical oncology, 1982, Volume: 19, Issue:4 Topics: Acidosis; Diarrhea; Female; Fenclonine; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid	1982
Effects of somatostatin infusion in four patients with malignant carcinoid syndrome. The American journal of gastroenterology, 1983, Volume: 78, Issue:3 Topics: Aged; Diarrhea; Female; Gastrins; Humans; Hydroxyindoleacetic Acid; Insulin; Male; Malignant Carcino	1983
Tryptophan in the treatment of carcinoid crisis. Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:2 Topics: Female; Humans; Hydroxyindoleacetic Acid; Laparotomy; Liver Neoplasms; Malignant Carcinoid Syndrome;	1983
Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. The New England journal of medicine, 1983, Jul-21, Volume: 309, Issue:3 Topics: Aged; Carcinoid Tumor; Chorionic Gonadotropin; Female; Humans; Hydroxyindoleacetic Acid; Ileal Neopl	1983
Simplified determination of serotonin in plasma by liquid chromatography with electrochemical detection. Clinical chemistry, 1984, Volume: 30, Issue:1 Topics: 5-Hydroxytryptophan; Adolescent; Adult; Catecholamines; Chromatography, High Pressure Liquid; Electr	1984
Ileal tumor causing carcinoid syndrome without hepatic metastases. Archives of surgery (Chicago, Ill. : 1960), 1984, Volume: 119, Issue:4 Topics: Humans; Hydroxyindoleacetic Acid; Ileal Neoplasms; Male; Malignant Carcinoid Syndrome; Middle Aged	1984
Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer treatment reports, 1984, Volume: 68, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cyclophosphamide; Drug	1984
The tricuspid valve in carcinoid syndrome. An echocardiographic study. Archives of internal medicine, 1983, Volume: 143, Issue:5 Topics: Carcinoid Heart Disease; Cardiac Catheterization; Echocardiography; Humans; Hydroxyindoleacetic Acid	1983
Embolization of the liver in the management of metastatic carcinoid tumors. Journal of surgical oncology, 1984, Volume: 27, Issue:3 Topics: Aged; Carcinoid Tumor; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Hydroxyindoleaceti	1984
Somatostatin inhibits diarrhea in the carcinoid syndrome. Annals of internal medicine, 1980, Volume: 92, Issue:1 Topics: Carcinoid Tumor; Creatinine; Diarrhea; Fasting; Feces; Female; Humans; Hydroxyindoleacetic Acid; Mal	1980
Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clinical chemistry, 1994, Volume: 40, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Platelets; Carcinoid Tumor; Cat	1994
Response to increasing doses of octreotide in a patient with carcinoid syndrome. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:16 Topics: Dose-Response Relationship, Drug; Female; Humans; Hydroxyindoleacetic Acid; Liver Neoplasms; Maligna	1993
[Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha]. Zeitschrift fur Gastroenterologie, 1994, Volume: 32, Issue:4 Topics: Biomarkers, Tumor; Combined Modality Therapy; Female; Gastrinoma; Gastrins; Gastrointestinal Neoplas	1994
Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Internal medicine (Tokyo, Japan), 1994, Volume: 33, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoid Tumor; Combined Modal	1994
[Pronounced flush symptoms in carcinoid syndrome without liver metastases]. Leber, Magen, Darm, 1994, Volume: 24, Issue:6 Topics: Aged; Cecal Neoplasms; Cecum; Diagnosis, Differential; Flushing; Humans; Hydroxyindoleacetic Acid; I	1994
Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites. Gastroenterology, 1995, Volume: 108, Issue:3 Topics: Adult; Aged; Catecholamines; Female; Flushing; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasm	1995
An improvement of the endocrine diagnosis by high-performance liquid chromatography. Romanian journal of endocrinology, 1993, Volume: 31, Issue:3-4 Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Chromatography, High Pressure Liquid; Chromatography	1993
Embolisation therapy in the midgut carcinoid syndrome: just tumour ischaemia? Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:2 Topics: Adult; Aged; Combined Modality Therapy; Embolization, Therapeutic; Female; Hepatic Artery; Humans; H	1993
Relation between fat malabsorption and transit abnormalities in human carcinoid diarrhea. Gastroenterology, 1996, Volume: 110, Issue:2 Topics: Aged; Aged, 80 and over; Celiac Disease; Colon; Diarrhea; Dietary Fats; Female; Gastric Emptying; Ga	1996
Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:9 Topics: Female; Humans; Hydroxyindoleacetic Acid; Indium Radioisotopes; Malignant Carcinoid Syndrome; Middle	1996
Pseudocarcinoid syndrome associated with hypogonadism and response to testosterone therapy. Mayo Clinic proceedings, 1996, Volume: 71, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Flushing; Humans; Hydroxyindoleacetic Acid; Hypogonadism; Mal	1996
Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut, 1996, Volume: 39, Issue:2 Topics: Biomarkers, Tumor; Diarrhea; Female; Flushing; Humans; Hydroxyindoleacetic Acid; Male; Malignant Car	1996
Acute renal failure associated with carcinoid crisis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1996, Volume: 11, Issue:12 Topics: Acute Kidney Injury; Antineoplastic Agents, Hormonal; Creatinine; Fatal Outcome; Humans; Hydroxyindo	1996
Urinary 5-hydroxyindole-acetic acid by high-performance liquid chromatography with electrochemical detection. Annals of clinical biochemistry, 1997, Volume: 34 ( Pt 4) Topics: Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Electrochemistry; Humans; Hydrox	1997
Carcinoid syndrome with unknown primary: a case report. American journal of clinical oncology, 1999, Volume: 22, Issue:4 Topics: 5-Hydroxytryptophan; Fatal Outcome; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Synd	1999
Gastrointestinal carcinoids: characterization by site of origin and hormone production. Annals of surgery, 2000, Volume: 232, Issue:4 Topics: Carcinoid Tumor; Databases, Factual; Female; Gastrointestinal Neoplasms; Hormones, Ectopic; Humans;	2000
Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. The British journal of surgery, 2001, Volume: 88, Issue:6 Topics: Adult; Aged; Female; Heart Valve Diseases; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasms; M	2001
Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. British journal of anaesthesia, 2001, Volume: 87, Issue:3 Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Carcinoid Heart Disease; Carcinoi	2001
The occurrence of malignant carcinoid syndrome in patients with carcinoid tumors. Bratislavske lekarske listy, 2002, Volume: 103, Issue:2 Topics: Adult; Aged; Carcinoid Tumor; Female; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasms; Male;	2002
Plasma amino acids in patients with the carcinoid syndrome. Cancer, 1976, Volume: 38, Issue:5 Topics: Aged; Amino Acids; Diabetes Mellitus; Fenclonine; Humans; Hydroxyindoleacetic Acid; Male; Malignant	1976
Pituitary-gonadal function in the carcinoid syndrome: effect of parachlorophynylalanine therapy. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1977, Volume: 9, Issue:2 Topics: Aged; Chorionic Gonadotropin; Clomiphene; Fenclonine; Follicle Stimulating Hormone; Humans; Hydroxyi	1977
Ultrastructural cytochemistry of platelets and megakaryocytes in the carcinoid syndrome. Mayo Clinic proceedings, 1976, Volume: 51, Issue:9 Topics: Acid Phosphatase; Aged; Blood Platelets; Cytoplasmic Granules; Female; Histocytochemistry; Humans; H	1976
Urinary free cortisol excretion in patients with hyperserotoninaemia from the carcinoid syndrome. Clinical endocrinology, 1979, Volume: 11, Issue:5 Topics: 5-Hydroxytryptophan; Adult; Aged; Carcinoid Tumor; Female; Humans; Hydrocortisone; Hydroxyindoleacet	1979
The carcinoid syndrome: methods of treatment and recent experience with hepatic artery ligation and infusion. Clinical oncology, 1977, Volume: 3, Issue:4 Topics: Female; Fluorouracil; Heart Failure; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Ileum; Intest	1977
Carcinoid apudomas. Current problems in cancer, 1977, Volume: 1, Issue:11 Topics: Adult; Aged; Appendiceal Neoplasms; Bronchial Neoplasms; Carcinoid Tumor; Female; Hormones, Ectopic;	1977
The carcinoid endocardial plaque; an ultrastructural study. Human pathology, 1976, Volume: 7, Issue:4 Topics: Endocardium; Heart Neoplasms; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome	1976
The effect of hepatic dearterialization and re-dearterialization on carcinoid liver metastases. Annales chirurgiae et gynaecologiae, 1976, Volume: 65, Issue:3 Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholesterol; Fem	1976
[Joint manifestations of carcinoid tumors of the digestive system]. Revue du rhumatisme et des maladies osteo-articulaires, 1976, Volume: 43, Issue:10 Topics: Finger Joint; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Joint Diseases; Malignan	1976
Editorial: Diagnosis of malignant carcinoid syndrome. British medical journal, 1975, Jul-19, Volume: 3, Issue:5976 Topics: 5-Hydroxytryptophan; Bronchial Neoplasms; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Synd	1975
Hepatic artery ligation in treatment of carcinoid syndrome. Canadian Medical Association journal, 1975, Feb-08, Volume: 112, Issue:3 Topics: Aged; Angiography; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Hydroxyindoleacet	1975
Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer, 1975, Volume: 36, Issue:2 Topics: Aged; Autopsy; Carcinoid Tumor; Dermoid Cyst; Female; Follow-Up Studies; Functional Laterality; Huma	1975
[Treatment of carcinoid syndrome with ocreotide (SMS-201-995)]. Revista clinica espanola, 1992, Volume: 191, Issue:3 Topics: Female; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Middle Aged; Octreotide	1992
Treatment of metastatic carcinoid tumour with recombinant interferon alfa. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10 Topics: Adult; Aged; Carcinoid Tumor; Female; Follow-Up Studies; Humans; Hydroxyindoleacetic Acid; Interfero	1992
Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyindoleacetic Aci	1992
[Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor]. Revista clinica espanola, 1991, Volume: 189, Issue:7 Topics: Aged; Carcinoid Tumor; Drug Evaluation; Humans; Hydroxyindoleacetic Acid; Jejunal Neoplasms; Liver N	1991
Management of disseminated midgut carcinoid tumours. Digestion, 1991, Volume: 49, Issue:2 Topics: Adult; Aged; Carcinoid Tumor; Combined Modality Therapy; Embolization, Therapeutic; Female; Hepatect	1991
Recombinant alpha-2b interferon in patients with malignant carcinoid tumour. Australian and New Zealand journal of medicine, 1991, Volume: 21, Issue:6 Topics: Adult; Aged; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid;	1991
The pentagastrin test in the diagnosis of the carcinoid syndrome. Journal of cardiovascular pharmacology, 1985, Volume: 7 Suppl 7 Topics: Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacetic Acid; Ketanserin; M	1985
Hepatic arterial embolisation in patients with metastatic carcinoid tumours. Clinical radiology, 1985, Volume: 36, Issue:6 Topics: Aged; Angiography; Carcinoid Tumor; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Hydro	1985
Endocrine tumors of the ileum. Cytochemical and clinical aspects. Pathology, research and practice, 1985, Volume: 180, Issue:4 Topics: Adult; Aged; Female; Follow-Up Studies; Hormones; Humans; Hydroxyindoleacetic Acid; Ileal Neoplasms;	1985
The carcinoid syndrome and multiple hormone secretion associated with a carcinoid tumour of the uterine cervix. Case report. British journal of obstetrics and gynaecology, 1986, Volume: 93, Issue:4 Topics: Adrenocorticotropic Hormone; Adult; Carcinoid Tumor; Chorionic Gonadotropin; Chorionic Gonadotropin,	1986
Do indole markers predict carcinoid heart disease? Chest, 1986, Volume: 90, Issue:1 Topics: Adult; Aged; Aortic Valve; Carcinoid Heart Disease; Female; Heart Valve Diseases; Humans; Hydroxyind	1986
Hepatic artery embolisation--new approach for treatment of malignant carcinoid syndrome. Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten, 1986, Volume: 46, Issue:2 Topics: Carcinoid Tumor; Combined Modality Therapy; Embolization, Therapeutic; Female; Hepatic Artery; Human	1986
Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology, 1986, Volume: 91, Issue:3 Topics: Adult; Aged; Eating; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; M	1986
Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. The Journal of clinical endocrinology and metabolism, 1986, Volume: 63, Issue:3 Topics: Adult; Aged; Chromatography, High Pressure Liquid; Eating; Ethanol; Female; Flushing; Humans; Hydrox	1986
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. The New England journal of medicine, 1986, Sep-11, Volume: 315, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Diarrhea; Female; Flushing; Humans; Hydroxyindoleacetic Acid; In	1986
Flushing in the carcinoid syndrome and plasma kallikrein. Cancer, 1986, Nov-15, Volume: 58, Issue:10 Topics: Adult; Aged; Bronchial Neoplasms; Carcinoid Tumor; Female; Flushing; Gastrointestinal Neoplasms; Hum	1986
[Urinary 5-HIAA stimulation test for the diagnosis of carcinoid syndrome caused by carcinoid tumors of the middle intestine]. Revista espanola de las enfermedades del aparato digestivo, 1986, Volume: 70, Issue:4 Topics: Calcium; Humans; Hydroxyindoleacetic Acid; Intestinal Neoplasms; Malignant Carcinoid Syndrome; Time	1986
[The echocardiogram in the carcinoid heart syndrome. A case report]. Arquivos brasileiros de cardiologia, 1986, Volume: 46, Issue:5 Topics: Adult; Blood Pressure; Carcinoid Heart Disease; Echocardiography; Female; Humans; Hydroxyindoleaceti	1986
Normal 5-hydroxyindole excretion in the presence of carcinoid syndrome. Irish medical journal, 1987, Volume: 80, Issue:4 Topics: Aged; Carcinoid Tumor; Diagnostic Errors; Female; Humans; Hydroxyindoleacetic Acid; Lung Neoplasms;	1987
Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Annals of surgery, 1987, Volume: 206, Issue:2 Topics: Adult; Aged; Bronchial Neoplasms; Diarrhea; Female; Flushing; Gastrointestinal Neoplasms; Heart Arre	1987
Carcinoid tumors and syndrome. Seminars in oncology, 1987, Volume: 14, Issue:3 Topics: 5-Hydroxytryptophan; Carcinoembryonic Antigen; Carcinoid Heart Disease; Carcinoid Tumor; Diagnosis,	1987
Hepatic dearterialization in the treatment of carcinoid syndrome. Acta chirurgica Scandinavica, 1987, Volume: 153, Issue:9 Topics: Adult; Aged; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Li	1987
Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation, 1988, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoid Heart Disease; Female; Heart Diseases; Humans; Hydroxyindo	1988
[Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon]. Onkologie, 1987, Volume: 10, Issue:6 Topics: Adult; Aged; Carcinoid Tumor; Cecal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies;	1987
Two cases of gastric carcinoids: diagnostic and therapeutic aspects. World journal of surgery, 1988, Volume: 12, Issue:3 Topics: Aged; Drug Therapy, Combination; Female; Humans; Hydroxyindoleacetic Acid; Imidazoles; Liver Neoplas	1988
SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization. Anesthesia and analgesia, 1988, Volume: 67, Issue:12 Topics: Aged; Embolization, Therapeutic; Female; Hemodynamics; Hepatic Artery; Humans; Hydroxyindoleacetic A	1988
Distinguishing features of idiopathic flushing and carcinoid syndrome. Archives of internal medicine, 1988, Volume: 148, Issue:12 Topics: Adult; Diagnosis, Differential; Female; Flushing; Humans; Hydroxyindoleacetic Acid; Male; Malignant	1988
Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. The American journal of cardiology, 1989, Feb-01, Volume: 63, Issue:5 Topics: Adult; Aged; Carcinoid Heart Disease; Echocardiography; Female; Heart Valve Diseases; Humans; Hydrox	1989
Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. Journal of the National Cancer Institute, 1989, Apr-05, Volume: 81, Issue:7 Topics: Aged; Antibody Formation; Biomarkers, Tumor; Carcinoid Tumor; Chorionic Gonadotropin; Female; Humans	1989
Partial remission of carcinoid tumor in response to cyproheptadine. Annals of internal medicine, 1989, Nov-01, Volume: 111, Issue:9 Topics: Aged; Aged, 80 and over; Carcinoid Tumor; Cyproheptadine; Female; Humans; Hydroxyindoleacetic Acid;	1989
[A prolonged-action somatostatin analog and carcinoid syndrome]. Bulletin de l'Academie nationale de medecine, 1989, Volume: 173, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Diarrhea; Female; Flushing; Humans; Hyd	1989
Carcinoid syndrome: an unusual cause of diarrhoea. Archives of disease in childhood, 1985, Volume: 60, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Diarrhea; Female; Humans; Hydroxyindoleacetic	1985
Hepatocellular carcinoma with the carcinoid syndrome. Cancer, 1971, Volume: 27, Issue:5 Topics: Acid Phosphatase; Adult; Albumins; Bile Acids and Salts; Carcinoma, Hepatocellular; Esterases; Fibri	1971
Carcinoid tumors: effect on thyroid function. The American journal of the medical sciences, 1973, Volume: 266, Issue:6 Topics: Adult; Aged; Alkaline Phosphatase; Bronchial Neoplasms; Carcinoid Tumor; Cholesterol; Female; Humans	1973
A carcinoid saga. The Australian and New Zealand journal of surgery, 1974, Volume: 44, Issue:1 Topics: Anesthesia, General; Aprotinin; Carcinoid Tumor; Female; Fluorouracil; Hepatectomy; Humans; Hydroxyi	1974
Chest pain in the carcinoid syndrome. Lancet (London, England), 1970, Jul-11, Volume: 1, Issue:7663 Topics: Aged; Chlorpromazine; Female; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Pain;	1970
[Pharmacological and therapeutic studies (p-chlorphenylalanin) on carcinoid syndrome in 11 cases]. Klinische Wochenschrift, 1971, Jul-01, Volume: 49, Issue:13 Topics: 5-Hydroxytryptophan; Aged; Blood Pressure; Bradykinin; Epinephrine; Female; Fenclonine; Humans; Hydr	1971
Glucose metabolism and insulin secretion in the carcinoid syndrome. The Journal of clinical endocrinology and metabolism, 1972, Volume: 35, Issue:2 Topics: Adult; Glucose; Glucose Tolerance Test; Humans; Hydroxyindoleacetic Acid; Insulin; Insulin Antagonis	1972
Streptozotocin treatment of metastatic carcinoid tumors. Southern medical journal, 1972, Volume: 65, Issue:11 Topics: Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Liver Neoplasms; Lung Neoplasms; Male; Malignant	1972
Carcinoid syndrome treated with streptozotocin. Proceedings of the Royal Society of Medicine, 1972, Volume: 65, Issue:2 Topics: Alkaline Phosphatase; Female; Histocytochemistry; Humans; Hydroxyindoleacetic Acid; Liver Neoplasms;	1972
Carcinoid myopathy and treatment with cyproheptadine (Periactin). Gut, 1974, Volume: 15, Issue:1 Topics: Acid Phosphatase; Cyproheptadine; Diarrhea; Feces; Female; Fenclonine; Humans; Hydroxyindoleacetic A	1974
Treatment of the carcinoid syndrome by hemihepatectomy and radical excision of the primary lesion. American journal of surgery, 1974, Volume: 128, Issue:1 Topics: Aged; Cyproheptadine; Diarrhea; Fenclonine; Heart Valve Diseases; Hepatectomy; Humans; Hydroxyindole	1974
Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine. Annals of internal medicine, 1970, Volume: 73, Issue:4 Topics: Adult; Aged; Animals; Behavior; Brain Chemistry; Catechols; Cattle; Depression; Diarrhea; Dogs; Enzy	1970
[The radiological diagnosis of carcinoids (author's transl)]. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1974, Volume: 121, Issue:2 Topics: Angiography; Carcinoid Tumor; Cecal Neoplasms; Gastrointestinal Neoplasms; Humans; Hydroxyindoleacet	1974
Ophthalmic manifestations of the carcinoid flush. The New England journal of medicine, 1967, Aug-24, Volume: 277, Issue:8 Topics: Adult; Aged; Blood Pressure; Epinephrine; Fundus Oculi; Humans; Hydroxyindoleacetic Acid; Intraocula	1967
[Carcinoid syndrome in primary esophageal tumor]. Zeitschrift fur Gastroenterologie, 1974, Volume: 12 Suppl, Issue:0 Topics: Esophageal Neoplasms; Humans; Hydroxyindoleacetic Acid; Liver Neoplasms; Male; Malignant Carcinoid S	1974
[Carcinoid tumors with double ileal and bronchial localization (apropos of a case)]. Journal de chirurgie, 1972, Volume: 104, Issue:5 Topics: Autopsy; Bradykinin; Bronchial Neoplasms; Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Ileum;	1972
Specific photometric determination of 5-hydroxyindoleacetic acid in urine. Clinical chemistry, 1973, Volume: 19, Issue:1 Topics: Color; Evaluation Studies as Topic; Female; Guaiacol; Humans; Hydrogen-Ion Concentration; Hydroxyind	1973
[Carcinoid cardiopathy. Apropos of a case]. Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1973, Volume: 18, Issue:1 Topics: Female; Heart Function Tests; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Middle	1973
The malignant carcinoid syndrome. Surgery, gynecology & obstetrics, 1973, Volume: 137, Issue:4 Topics: Adult; Aged; Appendiceal Neoplasms; Diarrhea; Erythema; Female; Humans; Hydroxyindoleacetic Acid; In	1973
Malignant carcinoid tumour with gangrene of the small intestine. British medical journal, 1973, Dec-29, Volume: 4, Issue:5895 Topics: Adult; Aged; Biopsy; Carcinoid Tumor; Diarrhea; Female; Gangrene; Humans; Hydroxyindoleacetic Acid;	1973
Catecholamine metabolism in the carcinoid syndrome. Clinica chimica acta; international journal of clinical chemistry, 1974, Feb-28, Volume: 51, Issue:1 Topics: Catecholamines; Creatine; Diagnosis, Differential; Epinephrine; Female; Homovanillic Acid; Humans; H	1974
Blood prostaglandin activity associated with noradrenaline-provoked flush in the carcinoid syndrome. The British journal of dermatology, 1974, Volume: 90, Issue:5 Topics: Aged; Alkaline Phosphatase; Blister; Body Weight; Carcinoid Tumor; Chromatography, Thin Layer; Diarr	1974
[Carcinoid syndrome. II. Clinical manifestations, diagnosis, prognosis and treatment]. Revista clinica espanola, 1974, Jan-31, Volume: 132, Issue:2 Topics: Antineoplastic Agents; Diarrhea; Epinephrine; Heart Valve Diseases; Humans; Hydroxyindoleacetic Acid	1974
Metastatic carcinoid to the liver treated by hepatic dearterialization. Annals of surgery, 1974, Volume: 180, Issue:3 Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Celiac Artery; Female; Hepatic Artery;	1974
[Carcinoid tumor of the small intestine complicated by endocardial fibrosis of the right heart]. Archives des maladies du coeur et des vaisseaux, 1971, Volume: 64, Issue:1 Topics: Aged; Carcinoid Tumor; Cyanosis; Dyspnea; Endocardial Fibroelastosis; Female; Humans; Hydroxyindolea	1971
The carcinoid syndrome in an elderly woman. Gerontologia clinica, 1971, Volume: 13, Issue:6 Topics: Aged; Chlorpromazine; Female; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Methyl	1971
[Carcinoid tumor of the ileum. Predominant lesions of the left endocardium]. Annales de medecine interne, 1971, Volume: 122, Issue:10 Topics: Autopsy; Celiac Artery; Endocardium; Heart Ventricles; Humans; Hydroxyindoleacetic Acid; Ileum; Inte	1971
[Ileal carcinoid tumors. Predominant lesions of the left endocardium]. Annales de medecine interne, 1971, Volume: 122, Issue:10 Topics: Angiography; Bradykinin; Chromatography; Endocardium; Heart Neoplasms; Humans; Hydroxyindoleacetic A	1971
Studies of the carcinoid syndrome: its relationship to serotonin, bradykinin, and histamine. Surgery, 1967, Volume: 61, Issue:6 Topics: Adult; Aprotinin; Bradykinin; Epinephrine; Gold Isotopes; Histamine; Humans; Hydroxyindoleacetic Aci	1967
[Laboratory findings in the carcinoid syndrome]. Deutsche medizinische Wochenschrift (1946), 1968, May-10, Volume: 93, Issue:19 Topics: 5-Hydroxytryptophan; Chromatography; Histamine; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoi	1968
[Carcinoid and the kallikrein-kinin system]. Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 1968, Volume: 349, Issue:7 Topics: Aprotinin; Humans; Hydroxyindoleacetic Acid; Kallikreins; Kinins; Liver Neoplasms; Malignant Carcino	1968
[A case of carcinoid syndrome and urolithiasis. Accidental coincidence or etiological connection]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1969, Nov-15, Volume: 89, Issue:22 Topics: Adolescent; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Urinary Calculi	1969
A single hepatic metastasis from bronchial carcinoid treated by right hepatectomy. The British journal of surgery, 1970, Volume: 57, Issue:3 Topics: Adenoma; Bronchial Neoplasms; Hepatectomy; Humans; Hydroxyindoleacetic Acid; Liver Neoplasms; Male;	1970
The carcinoid syndrome: chronic treatment with para-chlorophenylalanine. Annals of internal medicine, 1970, Volume: 72, Issue:6 Topics: Amino Acids; Chlorine; Diarrhea; Dopamine; Heart Valve Diseases; Hepatomegaly; Humans; Hydroxyindole	1970
[The carcinoid syndrome]. Ugeskrift for laeger, 1970, Jun-18, Volume: 132, Issue:25 Topics: Amino Acids; Chlorine; Enzyme Repression; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant	1970
[Carcinoid and carcinoid syndrome]. Ceskoslovenska gastroenterologie a vyziva, 1970, Volume: 24, Issue:7 Topics: Adult; Aged; Carcinoid Tumor; Diagnosis, Differential; Humans; Hydroxyindoleacetic Acid; Ileum; Inte	1970
[Bronchial carcinoid and carcinoid syndrome]. Sovetskaia meditsina, 1970, Volume: 33, Issue:12 Topics: Adenoma; Bronchial Neoplasms; Carcinoid Tumor; Female; Humans; Hydroxyindoleacetic Acid; Malignant C	1970
[The enterochromaffin system and clinical consequences of hyperserotonism]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1971, Mar-01, Volume: 26, Issue:5 Topics: Biopsy; Chromaffin System; Cyanosis; Depression, Chemical; Female; Heart Failure; Humans; Hydroxyind	1971
Discussion of the role of 5-hydroxyindoles in the carcinoid syndrome. Advances in pharmacology, 1968, Volume: 6, Issue:Pt B Topics: Carbon Isotopes; Ethanol; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Serotonin	1968
[The syndrome of metastazing carcinoid. 3. Long-term follow up of 5-hydroxyindoleacetic acid excretion in the urine]. Casopis lekaru ceskych, 1968, Volume: 107, Issue:13 Topics: Diuresis; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged	1968
Clinical aspects of indolealkylamine metabolism. Introductory remarks. Advances in pharmacology, 1968, Volume: 6, Issue:Pt B Topics: Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Phenylalanine; Serotonin	1968
A case of oat-cell carcinoma of the lung with the carcinoid syndrome. Postgraduate medical journal, 1968, Volume: 44, Issue:516 Topics: Carcinoma, Bronchogenic; Humans; Hydroxyindoleacetic Acid; Lung Neoplasms; Male; Malignant Carcinoid	1968
[Excretion of 5-hydroxyindoleacetic acid in carcinoid syndrome]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1968, Sep-15, Volume: 23, Issue:18 Topics: Circadian Rhythm; Creatinine; Diuresis; Humans; Hydroxyindoleacetic Acid; Kidney Function Tests; Kid	1968
Effect of 5-dydroxyindolylacetic acid in the colorimetric determination of urinary vanilmandelic acid. American journal of clinical pathology, 1969, Volume: 51, Issue:5 Topics: Colorimetry; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Mandelic Acids; M	1969
Effect of melphalan in the malignant carcinoid syndrome. Archives of internal medicine, 1969, Volume: 124, Issue:1 Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Hydroxyindoleacetic Acid; Liver; Male; Malignant Carc	1969
Surgical treatment of metastasizing carcinoid tumours. Acta chirurgica Scandinavica, 1969, Volume: 135, Issue:2 Topics: Hepatectomy; Humans; Hydroxyindoleacetic Acid; Ileum; Intestinal Neoplasms; Liver Function Tests; Li	1969
Massive hepatic resection for the carcinoid syndrome. Gut, 1969, Volume: 10, Issue:8 Topics: Adult; Hepatectomy; Humans; Hydroxyindoleacetic Acid; Ileum; Intestinal Neoplasms; Liver Neoplasms;	1969
Free and conjugated serotonin excretion in carcinoid syndrome. The Journal of laboratory and clinical medicine, 1965, Volume: 66, Issue:3 Topics: Chromatography, Ion Exchange; Chromatography, Thin Layer; Cyclophosphamide; Glucuronates; Glucuronid	1965
The competitive inhibition of amine oxidase with special reference to the carcinoid syndrome. Canadian journal of biochemistry, 1965, Volume: 43, Issue:7 Topics: Animals; Epinephrine; Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome; Monoamine Oxid	1965
The functioning carcinoid tumor: a serendipity in diagnosis. Transactions of the American Clinical and Climatological Association, 1966, Volume: 77 Topics: Adolescent; Adult; Ascites; Child; Female; Heart Failure; Humans; Hydroxyindoleacetic Acid; Ileum; I	1966
Dopamine and basal ganglia disorders. Neurology, 1965, Volume: 15, Issue:11 Topics: Adult; Basal Ganglia; Dopamine; Female; Hepatolenticular Degeneration; Humans; Hydroxyindoleacetic A	1965
The relationship between 5-hydroxyindoles and catecholamines. Neurology, 1965, Volume: 15, Issue:12 Topics: Blood-Brain Barrier; Brain Chemistry; Brain Diseases; Catecholamines; Dopamine; Female; Humans; Hydr	1965
Study of a possible physiologic interaction between ceruloplasmin and serotonin. The Journal of laboratory and clinical medicine, 1966, Volume: 67, Issue:6 Topics: Adolescent; Adult; Aged; Ceruloplasmin; Child; Female; Hepatolenticular Degeneration; Humans; Hydrox	1966
Some newer aspects of the carcinoid syndrome. Texas medicine, 1966, Volume: 62, Issue:12 Topics: Humans; Hydroxyindoleacetic Acid; Malignant Carcinoid Syndrome	1966